BCHT has launched Phase I clinical trials for the HSV-2 mRNA vaccine

Zhitong
2025.09.09 12:02

According to the "BCHT" WeChat official account, on September 9th, BCHT successfully held the launch meeting for the "Phase I dose escalation trial of HSV-2 mRNA vaccine in subjects aged 18 to 55 with different serological infections" at the Jishuitan Hospital in Beijing. The launch meeting provided systematic training and work deployment on core topics such as the background of genital herpes disease and vaccine development, GCP standards, clinical trial protocols, investigator manuals, sample management, and on-site processes. Subsequently, all preparatory work was orderly, and the subject enrollment process is about to be fully launched

Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.